Acute orbital, periorbital pain may signal arterial dissection
April 15th 2005Atlanta—Arterial dissection can be overlooked in a patient who presents to an ophthalmologist with acute orbital or periorbital pain. Val?rie Biousse, MD, described the appropriate steps to take to ensure an accurate diagnosis and avoid a subsequent cerebral insult.
Consider volume augmentation in PESS
April 15th 2005Austin, TX—Volume loss is an important aspect of post-enucleation socket syndrome (PESS), resulting from the inability of the prosthetic orbital implant to replace all of the volume lost from an enucleated or eviscerated socket. Fortunately, there are a number of effective techniques for volume augmentation in PESS, said John Shore, MD, FACS, who is in practice with Texas Oculoplastic Consultants, Austin, TX.
Multiple factors underlie non-compliance with treatment
April 15th 2005Dorado Beach, Puerto Rico—Recognizing that non-compliance and non-adherence are common among patients being treated with medical therapy for glaucoma, clinicians need to determine if medication is being used as prescribed, and if not, the reasons why, said Marshall N. Cyrlin, MD, at the Current Concepts in Ophthalmology meeting, sponsored by Johns Hopkins University School of Medicine and Ophthalmology Times.
No need to treat every patient with ocular hypertension
April 15th 2005St. Louis—The main lesson to be learned from the Ocular Hypertension Treatment Study (OHTS) is that not every patient with ocular hypertension needs to be treated, according to Michael A. Kass, MD, a professor in the department of ophthalmology and visual sciences at Washington University in St. Louis, and chairman of the groundbreaking large-scale study.
Updated mindset needed to combat glaucoma successfully
April 15th 2005New approaches to early detection, diagnosis, and management are essential to deal with the public health problem of glaucoma, the leading cause of blindness in the United States. Speakers at a continuing education symposium held during the American Academy of Ophthalmology meeting discussed topics such as the glaucoma continuum, application of the results of large clinical trials, global risk assessment principles, and pharmacotherapy.
Wavefront-guided LASIK better than conventional, but why?
April 15th 2005Wavefront-guided LASIK yields more accurate corrections and better quality of vision compared with conventional LASIK regardless of which laser system is used, said Robert K. Maloney, MD, at the American Academy of Ophthalmology refractive surgery subspecialty day meeting in New Orleans.
Interim results of hyperopic LASIK trial highly favorable
April 15th 2005Atlanta—Interim study analyses from a multicenter, North American trial indicate LASIK for treatment of hyperopia with or without astigmatism using the Nidek EC-5000 excimer laser is associated with consistently good safety and efficacy outcomes, reported George O. Waring III, MD, the medical monitor for the study.
Endophthalmitis higher with CCI than scleral tunnel
April 15th 2005San Francisco—A number of studies have suggested an increased rate of endophthalmitis with clear cornea surgery compared with scleral tunnel surgery, and potential causes of this increase include incision location, incision architecture and changes in antibiotic prophylaxis, according to David G. Hwang, MD.
Thoughts on transition to bimanual phaco
April 15th 2005For the past few years, the lure of ever smaller incisions has enticed cataract surgeons who perform temporal, clear corneal phacoemulsification with topical anesthesia. With a variety of shooters, we have been placing IOLs through 2.5- to 2.8-mm incisions and we feel comfortable with our self-sealing wounds and good results. Still, as many of us recall with previous transitions in our cataract surgery development, taking on a new skill requires stepping out of one's comfort zone to take advantage of even better technology. Such has been the situation with bimanual phacoemulsification.
Contrast sensitivity testing comes of age
April 15th 2005Contrast sensitivity testing has long been a technology that clinicians know has value, but the interpretation and implementation of the results were not clear. A number of recent scientific publications and new FDA standards have paved the way for contrast sensitivity to be more easily incorporated into routine clinical practice. This article traces the background of contrast sensitivity testing and some of the exciting developments related to its use in FDA clinical trials, for the management of "quality of vision," and for the monitoring and treatment of disease.
ARVO offers rich menu of educational opportunities
April 15th 2005Fort Lauderdale, FL—The theme of this year's annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) is "Global Networking." More than 9,000 scientists will be in attendance, and there will be in excess of 5,500 paper and poster presentations, more than 50 special events and presentations, and more than 100 exhibitors from which to choose. The conference begins Sunday, May 1, and wraps up on Thursday, May 5.
First patient tested with light-activated drug
April 15th 2005Seattle, WA—Visient Therapeutics Inc. has enrolled its first patient in a new phase I clinical trial to evaluate Light Infusion Technology (Litx) in patients with advanced age-related macular degeneration (AMD). The patient was treated by Gary Edd Fish, MD, at Texas Retina Associates in Dallas.